ACADIA Pharmaceuticals Inc. (ACAD) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-04
(Q2 2026)
— full calendar
Earnings Reports
-
Acadia Pharmaceuticals (ACAD) Q1 2026: Debut Sticks Drives 20% Growth, Pipeline Readouts Set $11B Opportunity in Motion
May 07, 2026
-
Acadia Pharmaceuticals (ACAD) Q4 2025: New Plazid Prescriber Base Expands 40% as Field Force Grows
February 26, 2026
-
Acadia Pharmaceuticals (ACAD) Q3 2025: Nuplazid Sales Jump 12% as Field Force Expansion Accelerates Growth
November 12, 2025
-
Acadia (ACAD) Q1 2025: Daybue Patient Base Rises to 954, Persistency Surpasses 65% Beyond Year One
July 04, 2025
-
Acadia Pharmaceuticals (ACAD) Q3 2024: Debut Patient Persistence Tops 60%, Underpinning Durable Rare Disease Growth
November 06, 2024
-
Acadia Pharmaceuticals (ACAD) Q2 2024: Nuplazid Guidance Raised $30M as DTC Campaigns Target Underpenetrated Markets
August 06, 2024
-
Acadia Pharmaceuticals (ACAD) Q1 2024: Debut Drives 74% Revenue Surge as Persistency Tops Clinical Benchmarks
May 08, 2024
-
Acadia Pharmaceuticals (ACAD) Q4 2023: Debut Drives 69% Revenue Surge, Expanding Rare Disease Platform
February 27, 2024